Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Merck Serono Stops Global Approval Process for Cladribine
July 4, 2011
- 3 Groups Reconfirm Opposition to Deregulating Online Sale of OTC Drugs
July 4, 2011
- Mebiopharm to Be Listed on TOKYO AIM on July 15
July 4, 2011
- Largest No. of New Drugs Listed in FY2010 in the Past 15 Years: FPMAJ
July 4, 2011
- JPA Presents Its Opinions on OTC Drug Risk Reclassification to Korosho
July 4, 2011
- Combined Sales of 23 Japanese Drug Companies Reach ¥100 billion in China
July 4, 2011
- Nihon Chouzai to Invest ¥10 Bil. to Increase GE Production Capacity
July 4, 2011
- Anticancer Drug Market in Japan to Exceed ¥1 Tril. in 2019: Fuji-Keizai
July 4, 2011
- Pfizer Japan to Promote Established Products with Force of 1,000
July 4, 2011
- Drug Market for Metabolic Diseases to Grow to ¥430 Bil. in 2019: Fuji-Keizai
July 4, 2011
- MTPC Expects 8 Launches in FY2011
July 4, 2011
- Generics of Actos Listed from 18 Companies
July 4, 2011
- MTPC, JCRS to Integrate Their Plasma Fraction Products Business in April 2012
July 4, 2011
- Actos Generics Launched Despite Various Issues
July 4, 2011
- Janssen, Takeda to Expand Share of Reminyl through Comarketing
June 27, 2011
- JACDS Draws Up GL for Power Saving This Summer
June 27, 2011
- TS-1 Non-Inferior to Gemcitabine in Pancreatic Cancer: Taiho
June 27, 2011
- Study Group to Discuss System for Relieving Victims of Health Damage Due to Anticancer Drugs
June 27, 2011
- Combined Sales of 24 Drug Makers Show Zero Growth
June 27, 2011
- FDA Approves Ciclesonide in Alternative HFA for Rhinitis: DSP
June 27, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…